Capricor Therapeutics (NASDAQ:CAPR) CFO Anthony Bergmann Sells 25,000 Shares of Stock

Capricor Therapeutics, Inc. (NASDAQ:CAPR) CFO Anthony Bergmann sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $30.13, for a total transaction of $753,250.00. Following the completion of the transaction, the chief financial officer directly owned 8,223 shares in the company, valued at approximately $247,758.99. This represents a 75.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Capricor Therapeutics Trading Up 6.6%

CAPR stock opened at $32.11 on Friday. The firm has a 50-day moving average of $27.20 and a two-hundred day moving average of $18.83. Capricor Therapeutics, Inc. has a 12 month low of $4.30 and a 12 month high of $40.37. The company has a market cap of $1.85 billion, a price-to-earnings ratio of -14.21 and a beta of 0.48.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Thursday, March 12th. The biotechnology company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.11). As a group, equities analysts forecast that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current year.

Hedge Funds Weigh In On Capricor Therapeutics

A number of hedge funds have recently modified their holdings of CAPR. Goldman Sachs Group Inc. grew its position in Capricor Therapeutics by 39.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 411,141 shares of the biotechnology company’s stock worth $3,902,000 after purchasing an additional 116,373 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Capricor Therapeutics by 6.8% in the 2nd quarter. Geode Capital Management LLC now owns 963,080 shares of the biotechnology company’s stock valued at $9,565,000 after purchasing an additional 61,701 shares during the last quarter. Legal & General Group Plc grew its stake in shares of Capricor Therapeutics by 8.4% in the 2nd quarter. Legal & General Group Plc now owns 41,273 shares of the biotechnology company’s stock valued at $410,000 after purchasing an additional 3,205 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of Capricor Therapeutics by 7.3% in the second quarter. Rhumbline Advisers now owns 53,450 shares of the biotechnology company’s stock valued at $531,000 after purchasing an additional 3,636 shares during the period. Finally, Marshall Wace LLP purchased a new stake in shares of Capricor Therapeutics during the second quarter worth approximately $796,000. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on CAPR. Oppenheimer boosted their target price on Capricor Therapeutics from $22.00 to $54.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. Maxim Group lifted their price objective on Capricor Therapeutics from $25.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, December 4th. Wall Street Zen downgraded Capricor Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, January 11th. B. Riley Financial raised their target price on shares of Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a report on Friday, March 13th. Finally, Cantor Fitzgerald set a $62.00 price target on shares of Capricor Therapeutics and gave the stock an “overweight” rating in a research note on Friday, March 13th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $46.09.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.